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Stenting of the venous outflow in chronic venous
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Jackson, Miss
Background: Stenting of chronic nonmalignant obstruction in the venous outflow tract started in earnest in 1997. Data
sets are now available to perform long-term analysis of stent-related outcome and clinical and hemodynamic results of this
intervention.
Materials: From 1997 to 2005, 982 chronic nonmalignant obstructive lesions of the femoroiliocaval vein were stented
under intravascular ultrasound guidance. Median patient age was 54 years (range, 14 to 90 years), the female/male was
2.6:1, and left/right limb symptoms, 2.4:1. Clinical score of CEAP was 2 in 7%, 3 in 47%, 4 in 24%, 5 in 5%, and 6 in 17%;
primary/secondary etiology was 518:464. Stent-related outcome (morbidity, thrombotic events, patency, in-stent
recurrent stenosis), clinical outcome, quality of life (QOL) as assessed by the Chronic Venous Insufficiency Quality of Life
Questionnaire (CIVIQ), and hemodynamics were evaluated before and after intervention.
Result: Monitoring for 94% of patients lasted a mean 22 months (range, 1 to 107 months). Stenting was performed with
no mortality (<30 days) and low morbidity. Thrombotic events were rare (1.5%) during the postoperative period (<30
days) and during later follow-up (3%). At 72 months, primary, assisted-primary, and secondary cumulative patency rates
were 79%, 100%, and 100% in nonthrombotic disease and 57%, 80%, and 86% in thrombotic disease, respectively.
Cumulative rate of severe in-stent restenosis (>50%) occurred in 5% of limbs at 72 months (10% in thrombotic limbs, 1%
in nonthrombotic limbs). The main risk factors associated with stent occlusion were the presence and severity of
thrombotic disease; thrombophilia by itself was not a risk factor. The median pain score and degree of swelling decreased
significantly poststent. Severe leg pain (visual analogue scale>5) and leg swelling (grade 3) decreased from 54% and 44%
prestent to 11% and 18% poststent, respectively. At 5 years, cumulative rates of complete relief of pain and swelling were
62% and 32%, respectively, and ulcer healing was 58%. The mean CIVIQ scores of QOL improved significantly in all
categories. Mean hand-foot pressure differential decreased and mean ambulatory venous pressure improved in stented
limbs with no concomitant reflux. The hemodynamic response was modified, depending on the presence of deep and
superficial reflux in subsets of patients with adjunct saphenous procedures. No increase in venous reflux was observed.
Conclusions: Venous stenting can be performed with low morbidity and mortality, long-term high patency rate, and a low
rate of in-stent restenosis. It resulted in major symptom relief in patients with chronic venous disease, which was not
consistently reflected in any substantial hemodynamic improvement by conventional measurements. The beneficial
clinical outcome occurred regardless of presence of remaining reflux, adjunct saphenous procedures, or etiology of
obstruction. (J Vasc Surg 2007;46:979-90.)Venous outflow obstruction plays an important role in
the clinical expression of chronic venous disease.1 The
combination of reflux and obstruction gives the highest
levels of venous hypertension and the most severe symp-
toms compared with either alone.2,3 Chronic obstruction
of the iliac vein, which is the common outflow tract of the
lower limb, results in severe symptoms because of poor
compensation by collateral formation.4,5 Only 20% to 30%
of thrombosed iliac veins treated by anticoagulation alone
completely recanalize. Five years later, the remaining ob-
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doi:10.1016/j.jvs.2007.06.046struction results in venous claudication in 44% and venous
ulcer in 15% of patients.6,7 The recanalization process
appears to be worse in the presence of an external compres-
sion, which has been reported in 80% of limbs with an acute
iliofemoral deep vein thrombosis (DVT).8,9
The existence of iliac vein compressions and intralumi-
nal webs is in itself more pathogenic than previously
thought because they were considered a common finding
of little clinical importance. This nonthrombotic iliac vein
lesion (NIVL) is found as often as post-thrombotic ob-
struction in chronic venous disease involving the iliofemo-
ral venous segment. It may occur in both the right and left
lower limbs in both sexes at all ages and involve both the
common and the external iliac veins. It is a major compo-
nent of symptomatic primary disease.10
Percutaneous endovenous stenting has emerged dur-
ing the last decade as the method of choice to treat
femoroiliocaval venous outflow obstruction due to
chronic venous disease. It has replaced bypass surgery as
the primary treatment. Stents have also been placed to
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iofemoral thrombus or caused by malignant tumors or
retroperitoneal thrombosis.8,9,11,12
Because the long-term outcome of the stenting proce-
dure is related to the underlying etiology and the clinical
situation, this study is limited to assess treatment in patients
with chronic, nonmalignant obstructions. Stent placement
started in earnest in our institution in 1997, and this
experience has formed the basis for several reports on
various aspects of venous stenting.13-18 Data sets are now
available to perform long-term analysis of this group of
patients; thus, the aim of this study is to evaluate procedure
and long-term stent-related outcome, clinical outcome,
and hemodynamic before and after results.
MATERIAL AND METHODS
From February 1997 to April 2005, 982 consecutive
chronic nonmalignant obstructive lesions of the femo-
roiliocaval vein were treated in 870 patients. Limbs treated
by thrombolysis before stenting are excluded. A time-
stamped electronic medical records program for patients
with venous disease was specifically constructed to prospec-
tively collect comprehensive standardized information on
symptoms and physical findings in patients with venous
disease.
The limbs were classified using the CEAP classification
according to the Reporting Standards of International So-
ciety of Cardiovascular Surgery (ISCS)/Society for Vascu-
lar Surgery (SVS).19,20 The obstructive lesion was consid-
ered thrombotic when the patient had a known history of
previous DVT or when post-thrombotic changes in the
lower extremity were found on venogram, or duplex or
intravascular ultrasound imaging (IVUS).
The following evaluations were performed before and
after the intervention: ascending and transfemoral ante-
grade venography,21,22 duplex Doppler study with stan-
dardized compression,23,24 ambulatory dorsal foot venous
pressure measurements, arm/foot pressure differential and
dorsal foot venous hyperemia-induced pressure increase,25
and air plethysmography (APG-1000; ACI Medical Inc,
Sun Valley, Calif).26 For a detailed description of the sup-
porting studies see Appendix Table EI (online only).
Thrombophilia testing was performed in 683 patients, in-
cluding levels of proteins C and S, antithrombin III, anti-
cardiolipins immunoglobulin (Ig) M and IgG, and homo-
cysteine, and the presence of lupus anticoagulant, factor V
Leiden, homocysteine gene, and prothrombin gene muta-
tion.
Intervention. The diagnosis of obstruction, indica-
tions for iliofemoral stenting, technical details of en-
dovenous stenting, and perioperative anticoagulation
treatment have been described previously.13,15,16,27 An
ultrasound-guided access to the femoral vein was ob-
tained and a sheath was inserted below the obstruction in
symptomatic patients with suspicion of obstruction. Af-
ter transfemoral venography, IVUS imaging was per-
formed. The crosscut area of the stenosis was measured
by IVUS and compared with the area of the normal veinbelow the stenosis, providing the percentage of stenosis.
Stents were placed in limbs shown to have 50% mor-
phologic stenosis by IVUS imaging. The transverse lu-
men area was obtained by IVUS imaging during the
intervention before and after stenting.
The partially obstructed segment was balloon-dilated and
stented under IVUS guidance to ensure that the entire lesion
was covered (Figs 1 and 2). Occluded post-thrombotic veins
required guidewire recanalization before stenting. Walls-
tents (Boston Scientific, Natick, Mass) were placed in 963
limbs (98%), and 19 limbs (2%) had nitinol stents placed.
Stenting of a stenosis adjacent to the confluence of the
common iliac veins using Wallstents required that the stent
be placed well into the inferior vena cava (IVC) to avoid
early restenosis. When two or more stents were inserted,
the stents were overlapped by at least 1 cm to ensure
adequate stent cover of the diseased vein without skipped
areas. Procedure details were collected in a specifically
designed database. The stenting was combined with proce-
dures controlling superficial venous reflux (great saphenous
vein [GSV] ablation/small saphenous vein [SSV] strip-
ping/stab avulsions) in the same session in 197 limbs (see
Appendix Table EII for details, online only). Compression
and local ulcer therapy in use preoperatively was continued
after intervention until healing. Prolonged use of the com-
pression regimen was generally not encouraged because
many considered it a quality-of-life issue. Noncompliant
patients were not fitted with new stockings.
Follow-up. Clinical follow-up for treated limbs was at
6 weeks, 3months, 9months, and then annually. The study
end point of legs with stasis ulceration was complete epi-
thelialization. Primary nonhealing ulcers were marked as
such and censored at 3 months. Any breakdown of an ulcer
after healing was considered a recurrence. The degree of
pain was evaluated perioperatively using a visual analog
scale (VAS) from 0 to 10, wherein 10 is the most severe
pain.28 Swelling was assessed according to reporting stan-
dards as grade 0, absent; grade 1, pitting, not obvious;
grade 2, visible ankle edema; and grade 3, massive, encom-
passing the entire leg. Patients were asked to complete the
Chronic Venous Insufficiency Quality of Life Question-
naire (CIVIQ) assessing subjective pain, sleep disturbance,
morale and social activities, and routine and strenuous
physical activities prospectively before intervention and
again at each postoperative visit. The CIVIQ form has a
proven specificity and relevance to chronic venous dis-
ease.29 The last available response was used in postoperative
outcome analysis. Venous function studies were repeated
on follow-up.
The degree of in-stent restenosis and patency was as-
sessed by an antegrade transfemoral venogram. In-stent
restenosis, if present, was assessed as the percentage diam-
eter reduction of the patent lumen of the stent. An ascend-
ing venogram through a dorsal foot vein and duplex ultra-
sound imaging was also used to evaluate stent patency but
not in-stent restenosis. The investigations were performed
at 2 to 3 months, 9 months, and then annually after
stenting.
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dian with range or mean SD, unless otherwise indicated.
Continuous variables were analyzed by t test or nonpara-
metric Wilcoxon rank test for paired and unpaired data,
depending on skewness, and the Fisher exact test for cate-
goric variables. Primary, assisted primary (patency after
preemptive intervention), and secondary patency (patency
after intervention for occlusion) rates as defined by the
reporting standards of the ISCVS/SVS19 were calculated
using survival analysis with the Kaplan-Meier method. Cu-
mulative survival analysis was also used to analyze and
compare recurrence of pain, swelling, and ulcer after the
treatment. The log-rank test was used to compare cumula-
tive curves Commercially available statistical programs
Graph Pad Prism 3.0 (GraphPad Software, San Diego,
Calif) and SAS 9.1 (SAS Institute, Inc, Cary, NC) were
used for analysis. Results are reported using P values and
either effect or odds ratio for continuous and categoric
variables, respectively. A P  .05 was considered signifi-
cant.
RESULTS
This study includes 982 limbs in 870 patients, of whom
112 patients (13%) had bilateral treatment with stents for
Fig 1. Left panel, Transfemoral venogram shows a ty
translucency at the vessel-crossing and transpelvic coll
ultrasound (IVUS) image of the left panel before and afte
by the stenosis at predilation before stent placement. R
collaterals. Note that the Wallstent is placed well into the
is carried into the external iliac vein because a significant
vein confluence. C and D, Inserts show before and after s
IVUS catheter.)obstruction of the femoroiliocaval vein. Median age was 54years (range, 14 to 90 years). Female gender and left lower
limb involvement were more than twice as common as male
gender and right lower limb (female/male ratio, 2.6:1;
left/right symptomatic limb ratio, 2.4:1). The CEAP clin-
ical score was class 2 in 7% of limbs, class 3 in 47%, class 4 in
24%, class 5 in 5%, and class 6 in 17%. Thus, almost half of
the patients had lower limb hyperpigmentation, dermatitis,
lipodermatosclerosis, healed venous ulcer, or active ulcer.
Most patients complained of limb pain (76%) and swelling
(82%). Limbs of C class 2 were chosen for the procedure
because of their associated pain. The etiology (E in CEAP)
was primary (NIVL) in 518 limbs and secondary (post-
thrombotic) in 464.
Obstruction of the deep venous outflow with no reflux
(P in CEAP) was found in 353 limbs (obstruction, 36%;
reflux/obstruction, 64%). Guidewire recanalization was
necessary in 62 occluded iliac veins in 464 post-thrombotic
limbs (13%). In the 629 limbs with reflux and obstruction,
reflux was found in 164 (26%) in the deep system alone, in
396 (63%) in the superficial system alone, and in 67 (11%)
of limbs in combined systems (A in CEAP: deep veins, 53%;
deep and superficial veins, 47%). Deep reflux was found in
24% of all limbs (236 of 982) and found to be axial (Kistner
grade 3 to 4) in 75% (177 of 236). The median multiseg-
nonthrombotic iliac vein lesion (NIVL) with prestent
s. A and B, Inserts show corresponding intravascular
ting.Middle panel,Waisting of balloon during inflation
panel, A venogram after stenting shows no stenosis or
ior vena cava to prevent retrograde migration. The stent
sis was found on IVUS at the external and internal iliac
ng IVUS. (a, artery; the black circle within the vein is thepical
ateral
r sten
ight
infer
steno
tentiment score was 1.8 (range, 1 to 7). Grade 2 to 4 obstruc-
er occ
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an additional 36% had reduced phasicity of the femoral vein
without pressure changes before stenting.
Post-stenting complications. The stenting proce-
dures were performed with no mortality (30 days). In the
first 29 cases, two access-related complications occurred
(7%) (1 retroperitoneal bleeding, 1 femoral artery injury
requiring open repair). Ultrasound-guided access in the
next 953 limbs limited cannulation complications to three
femoral artery pseudoaneurysms, which were treated by
thrombin injection, and an arteriovenous fistula, which
closed spontaneously (0.004%). In one patient the guide-
wire became caught in the stent, which was pulled to the
femoral vein and then openly removed. During the
follow-up period, 47 thrombotic events occurred in 982
patients (5%).
All early thrombotic events (<30 days). Early
thrombosis of the stented iliac vein occurred in 8 limbs, of
the contralateral iliac vein in 4 limbs, at the femoral access
site in 2 limbs, and was limited to the calf in 1 limb, for an
overall rate of 1.5%. All 12 iliac thrombi occurred in post-
thrombotic limbs. All the contralateral DVTs were lysed
successfully. Six limbs with stent occlusions had thrombol-
ysis, which was successful in three. A Palma crossover
bypass was performed in one patient. One patient with
occluded stent had an immediate thrombectomy, but this
Fig 2. Chronic iliofemoral thrombotic stenosis before
femoral vein to ensure an adequate inflow to prevent latrethrombosed after 3 weeks. One of the access-relatedfemoropopliteal vein thrombi was successfully lysed. The
calf DVT was treated by anticoagulation only.
All late thrombotic events. Occlusion of the stented
iliofemoral vein occurred at a median of 13 months (range,
2 to 77 months) after stenting in 23 limbs, for an overall
rate of 3%. In nine limbs, the occlusion was found at routine
follow-up and treated only by anticoagulation. Early onset
(7 days) occurred in 13 limbs, and thrombolysis was
attempted. This was successful in only four limbs, and the
other limbs remained occluded. One patient had an open
thrombectomy, which occluded in the postoperative pe-
riod. Late acute thrombotic events occurred in the con-
tralateral iliofemoral vein in seven limbs: one at the ipsilat-
eral receiving femoral site of an old axillary vein transfer,
and one nonocclusive thrombus was found attached to the
proximal site of a stent in the IVC. The latter two limbs
were treated only by anticoagulation. The IVC thrombus
could not be detected at a later investigation. All limbs with
contralateral proximal occlusions received thrombolysis,
which was successful in five of seven limbs.
Contralateral iliac vein thrombosis. As already de-
scribed, contralateral iliofemoral thrombosis occurred in 11
of 982 patients (1%) during the observation period. Three
limbs were stented for NIVL and eight limbs for throm-
botic obstructions. Nine of 11 limbs were successfully
fter stenting. The stenting is carried into the common
lusion.and alysed.
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trasound imaging was performed one or several times in
610 limbs (62%) to verify patency at a mean of 30 months
(range, 1 to 107 months) after stent placement. Ipsilateral
early or late stent occlusion occurred in 31 limbs and was
successfully lysed in seven; thus, 24 stents remained oc-
cluded. Overall primary, assisted-primary, and secondary
cumulative patency rates at 72 months were 67%, 89% and
93%, respectively (Fig 3). During the observation period,
149 secondary procedures were performed 1-97 months
(mean, 19 months) after initial stenting to maintain pa-
tency (in-stent restenosis 50%) or to treat unresolved or
recurrent symptoms. Additional stenting of stenosis above
and the below previous stent was performed in 14 and 63
limbs, respectively; balloon angioplasty of in-stent resteno-
sis in 56 limbs, and a combination of these procedures in 13
limbs. Stents were inserted in three limbs to bridge a
stenotic skip area between previously inserted stents.
The stented limbs with NIVL fared significantly better
(P  .0001) than did those with thrombotic disease, with
primary, assisted-primary, and secondary cumulative pa-
tency rates of 79%, 100%, and 100%, and 57%, 80%, and
86% at 72 months, respectively (Fig 4). The recanalized
post-thrombotic limbs had the highest occlusion rates after
stenting, with primary and secondary patency rates of 54%
and 74% at 48 months (Appendix Fig, online only). The
cumulative rate of severe in-stent restenosis (50%) was
assessed. The overall cumulative rate was 5% of limbs at 72
months and was higher in thrombotic limbs at 10% com-
pared with 1% in NIVL limbs (P  .0253; Fig 5).
Factors associated with iliac vein stent thrombosis.
During the observation time, 31 iliac stents occluded. All of
the occluded limbs had thrombotic (secondary) obstruc-
tion. Thrombophilia test was available in 75% (454 of 610)
of limbs included in the patency analysis and 38% (173 of
454) were positive. The test was positive for one or several
factors in 23% (105 of 454) of post-thrombotic limbs
Fig 3. Cumulative primary, assisted-primary, and secondary pa-
tency rates of 603 limbs after iliofemoral stenting. The lower
numbers represent limbs at risk for each time interval (all standard
error of the mean 10%).compared with 14% (29 of 209) in NIVL limbs (P .001,Fisher’s Exact test). There was an over-representation of
treated recanalized veins in the thrombosed stents (65%
thrombosed vs 9% patent stents, P  .001).
The proportional contribution of different factors to
stent occlusion was analyzed (Tables I and II). The inter-
vention side (left or right lower limb) and gender did not
increase the risk of occlusion, but younger age appeared to
do so. Of interest was that thrombophilia was more fre-
quent in limbs with thrombotic disease but was not statis-
Fig 4. Cumulative primary, assisted-primary, and secondary pa-
tency rates for stented limbs with nonthrombotic iliac vein lesions
(NIVL) and those with previous thrombosis. The lower numbers
represent total limbs at risk for each time interval (all standard error
of the mean 10%).
Fig 5. Cumulative rates of severe in-stent restenosis (50% nar-
rowing) in the entire study group for limbs stented for post-
thrombotic lesions (thrombotic) and for limbs stented for obstruc-
tion caused by nonthrombotic iliac vein lesions. The lower
numbers represent total limbs at risk for each time interval (all
standard error of the mean 10%).tically associated with stent occlusion. Thrombotic etiology
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extension into the common femoral vein were significantly
associated with stent occlusion. The preoperative crosscut
area of the stenosis, percentage stenosis on IVUS imaging,
and occlusion requiring recanalization before stenting all
reflect degree of stenosis and are significantly associated
with thrombosis of the stent.
Factors associated with in-stent restenosis. The
proportional contribution of different factors to develop-
ment of severe in-stent restenosis (50%) was analyzed
(Tables III and IV). Factors associated with restenosis are
similar to those associated with stent occlusion, except that
age is not associated with restenosis. The presence of
thrombotic disease is the dominating factor.
Clinical outcome. All 982 limbs, regardless of stent
outcome, are included in the final analysis of the clinical
outcome as an intent-to-treat study. Postinterventional
clinical follow-up was a mean of 24 months (range,
1 month to 8.75 years), allowing cumulative long-term
analysis. Information was available in 918 of 982 limbs
(93%). Before treatment, 24% of limbs were completely
pain-free, and 18% had no swelling. The preoperative and
postoperative mean pain and swelling scores improved sub-
stantially: 3.7 (range, 0 to 9) and 0.8 (range, 0 to 10), and
1.7 (range, 0 to 3) and 0.8 (range, 0 to 3), respectively (P
.0001). The rate of limbs with severe pain (5 on VAS) fell
from 41% to 11% after intervention, and gross swelling
(grade 3) in limbs decreased from 36% to 18%. As shown in
Table I. Odds ratios for possible factors contributing to
early (30 days) or late occlusions of inserted stents
Factor
Occluded,
frequency,
No. (%)
Odds
ratio* P†
Missing
values
Operation side 1.1 .8395
Left 22 (5.0)
Right 9 (5.3)
Etiology of obstruction — .0001
NIVL 0 (0.0)
Thrombotic 31 (10.1)
Degree of obstruction 9.0 .0001
Occlusion 12 (24.0)
Non-occlusive
obstruction
19 (3.4)
Thrombophilia test 1.2 .8261 159
Negative 17 (5.5)
Positive 7 (4.8)
Stent extended to CFV 3.8 .0010
Yes 12 (12.8)
No 19 (3.7)
Gender 1.4 .4090
Female 21 (4.7)
Male 10 (6.3)
Additional procedures 1.9 .3670
Yes 4 (5.6)
No 27 (3.1)
NIVL, Nonthrombotic iliac vein lesion; CFV, common femoral vein.
*Effect was computed as odds ratio.
†Computed by the Fisher exact test.Fig 6, cumulative freedom of pain and swelling were notstatistically different whether or not an additional saphe-
nous procedure was performed (P .8853 and P .5708,
respectively). This graph is based on complete relief of
swelling and pain (grade 0 swelling and 0 level of pain) and
does not reflect partial improvement. After 5 years overall,
62% and 32% remained completely free of pain and swell-
ing, respectively. The preoperative and postoperative mean
pain and swelling scores in the subsets of limbs with NIVL
and thrombotic obstruction improved to the same degree
in both groups. When cumulative outcome curves of com-
plete relief were compared at 5 years, there was no signifi-
cant difference in pain outcome (thrombotic and NIVL
limbs, 59% and 65%, respectively, P  .7215). Limbs with
thrombotic disease were, however, more frequently entirely
free of swelling than NIVL limbs (39% and 24%, P 
.0041).
Ulcer healing. Healing of leg ulcers was followed up
in 148 of 158 limbs for a mean 23 months (range, 1 to 99
months). In 47 limbs the ulcer did not heal. In the remain-
ing 101 limbs, the ulcer healed and recurred in only eight
limbs during the follow-up period. Thus, if healing of the
ulcer was achieved after this intervention, ulcer recurrence
was rare within the study period. The cumulative rate of
ulcer healing at 5 years was 58% overall (50% with stent
alone and 57% with additional procedure, P  .9754; 62%
for NIVL and 55% for thrombotic limbs, P  .2819; Fig 7).
Quality of life. The quality-of-life (QOL) question-
naire was introduced later in the study, explaining the
shorter mean follow-up of 5 months (range, 1 to 79
months) and the smaller number of patients (n  381).
There was significant improvement in all QOL categories
after treatment (Table V). The population of patients with
no or little effect on QOL increased substantially (doubled
in 3 of 5 categories). The CIVIQ score was the same in
patients with thrombotic and NIVL limbs before stenting
and decreased significantly in both groups of patients after
the procedure. Adjunct procedures did not affect the QOL
scores.
Hemodynamic outcome. To adequately assess the
hemodynamic impact after successful stenting, 63 limbs
with occluded stents or 50% in-stent stenosis were ex-
cluded from preintervention to postintervention hemody-
namic comparison (919 limbs remaining). The hemody-
namic results in the entire group and subsets of limbs with
stenting combined with saphenous procedures and stent-
ing alone are presented in Table VI. All limbs with adjunct
correction of superficial reflux had a greater meanmultiseg-
ment score (stent with added procedure and stenting alone,
2.3  1.6 and 1.4  1.7, respectively; P  .0001). The
prevalence of axial deep reflux was the same in both groups
of limbs (18%). After stenting, the improvement of venous
filling time (VFT), venous filling index (VFI90), and venous
volume (VV) was associated with the adjunct procedures.
The mean ambulatory venous pressure (AVP), however,
was improved regardless of whether an adjunct procedure
was performed, although the ejection fraction and residual
volume fraction remained unchanged. The hand-foot pres-
sure differential improved in limbs having stenting alone.
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reflux were compared with those stented in the presence of
reflux, which was left untreated (Table VII). This compar-
ison shows the true hemodynamic influence by stenting
alone in limbs with and without reflux. Except for decrease
of the hand-foot pressure differential in both groups, only
ambulatory pressure was decreased in the nonrefluxing
group after stenting.
Hemodynamics and etiology of obstruction.
Comparison of the thrombotic with NIVL limbs revealed a
greater multisegments score (2.2 1.9 and 1.1 1.3; P
.0001) and higher rate of deep axial reflux (32% and 6 %;
P  .0001). The hemodynamic results in the two stented
Table II. Variables tested for effect on patency
Variable Patent (n  576)* Occlu
Before stenting
Stenosis on IVUS, % 74.6  19.8 8
Area by IVUS, cm2 0.50  0.34 0
Patient age, y 54.0  13.7 4
Stents, No. 1.7  0.9
IVUS, Intravascular ultrasound.
*Values are presented as mean  standard deviation.
†Effect was computed as T statistic.
‡Computed two independent samples t test.
Table III. Odds ratios for possible factors contributing
to the development of severe in-stent recurrent
stenosis (50%) in inserted stents
Factor
Restenosis
50%,
frequency,
No. (%)
Odds
ratio* P†
Missing
values
Operation side 1.3 .3908
Left 30 (7.3)
Right 15 (9.4)
Etiology of obstruction 26.7 .0001
NIVL 2 (1.0)
Thrombotic 43 (15.5)
Degree of obstruction 8.3 .0001
Occlusion 14 (34.2)
Non-occlusive
obstruction 31 (5.9)
Thrombophilia test 1.2 .7026 151
Negative 23 (7.9)
Positive 12 (9.3)
Stent extended to CFV 5.5 .0001
Yes 19 (23.5)
No 26 (5.3)
Gender 1.6 .2093
Female 30 (7.0)
Male 15 (10.5)
Additional procedures 1.8 .2521
Yes 6 (5.0)
No 39 (8.7)
NIVL, nonthrombotic iliac vein lesion; CFV, common femoral vein.
*Effect was computed as odds ratio.
†Computed by the Fisher exact test.subgroups of primary and secondary etiology are given inTable VIII. Limbs with adjunct procedures to control
reflux were excluded. After intervention, the hand-foot
pressure differential improved in both sets of limbs. The
ambulatory venous pressure, ejection fraction, and residual
volume fraction improved in the NIVL limbs, indicating a
global improvement of the hemodynamics and more effi-
cient calf muscle pump. The hemodynamic effect of stent-
ing was minimal in the thrombotic limbs, and residual
volume fraction remained unchanged despite a decrease in
ejection fraction.
Hemodynamics and axial reflux. Axial reflux due to
primary (39 limbs) and thrombotic disease (138 limbs) was
present in 177 of 982 limbs (18%). Except for improve-
ment of the hand-foot pressure differential after stenting,
all other parameters remained unchanged in this group of
limbs after stenting. No enhancement of the retrograde
reflux was observed as measured by VFT or VFI90, neither
in limbs with primary nor secondary axial reflux.
Hemodynamics and clinical symptoms. Before stent-
ing, ambulatory venous pressure was higher (42 19% and
58 21% drop), VFT shorter (10 6 seconds and 16 15
seconds), and VFI90 greater (5.1  2.5 mL/s and 3.3 
1.5 mL/s) in nonhealing limbs compared with healing
limbs. Other hemodynamic results were the same in both
groups. After stenting, all parameters remained unchanged
in both limb groups when limbs with the adjunct proce-
dures were excluded. As stated above, the cumulative rate
for ulcer healing was the same whether or not an adjunct
procedure was performed.
There was no difference in cumulative freedom of pain
and swelling whether or not additional saphenous proce-
dure was performed. When limbs with an adjunct proce-
dure were excluded from the calculations, all except the
hand-foot pressure differential remained unchanged. This
pressure decreased significantly in both groups of limbs,
with complete pain and swelling relief (1.2  1.3 to 0.7 
1.0 [P  .0087] and 1.6  1.7 to 0.8  1.4 [P  .0147],
respectively).
DISCUSSION
Stenting of the venous outflow obstruction of the lower
extremities can be performed with low risk, long-term high
patency rate, and a low rate of in-stent restenosis. It resulted
in major symptom relief in patients with chronic venous
(n  31) Effect† P‡ Missing values
19.2 3.24 .0013 69
0.39 3.58 .0004 186
14.8 3.51 .0005
0.9 4.97 .0001 11ded*
7.2 
.21 
5.1 
2.5 disease, which was not consistently reflected in any substan-
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ments. The beneficial clinical outcome occurred regardless
of the presence of remaining reflux, adjunct saphenous
procedures, or etiology of obstruction.
Although the literature has numerous small case re-
ports, only a few larger series with acceptable short-term to
mid-term follow-up have been published. Most of these
reports mix limbs stented for chronic obstruction with
those stented after clot removal.30,31 A recent retrospective
analysis of 50 stented patients was reported.32 Nearly half
the patients had lysis before stenting, and more than 90%
had thrombotic obstruction. Cumulative primary, assisted-
primary, and secondary patency rates at 48 months were
58%, 71%, and 83%, respectively. Hartung et al33 reported
results of iliocaval stenting in 44 patients with chronic
obstruction of primary, secondary, and congenital etiolo-
gies in 32, 10, and 2 limbs, respectively. Stenting was not
preceded by thrombolysis. Overall cumulative primary,
assisted-primary, and secondary patency rates at 36 to 60
Table IV. Variables tested for effect on development of se
Variable Restenosis 50%* (n  525)
Before stenting
Stenosis on IVUS 73.9  19.5
Area by IVUS, cm2 0.51  0.34
Patient age, y 54.0  13.7
Stents, No. 1.64  0.82
IVUS, Intravascular ultrasound.
*Values are written as mean  standard deviation.
†Computed as T statistic.
‡Computed 2 independent samples t test.
Fig 6. Cumulative sustained complete relief of pain and swelling
after femoroiliocaval stenting in patients who had stent placement
alone and in those with additional procedures. These curves do not
reflect partial improvement only. Only limbs that had preoperative
pain or swelling are shown. The lower numbers represent limbs at
risk for each time interval (standard error of the mean 10%).months were 73%, 88%, and 90%, respectively, with inten-tion to treat. Their results are comparable with those found
in the present study.
Primary and secondary patency rates were obviously
mainly related to the presence and severity of thrombotic
disease. Further analysis of possible contributing factors
confirmed that tight, long lesions of thrombotic etiology
requiringmultiple stents reaching caudad into the common
femoral vein were of greatest risk to occlude. Even though
the thrombotic state was such a high risk factor, the pres-
ence of thrombophilia in itself was not significantly associ-
ated with occlusion. The operation side and gender did not
influence stent outcome, but younger age appeared to do
so. Knipp et al32 found that gender, recent trauma, and age
younger than 40 years were predictive of decreased primary
patency. The different finding may be explained by selec-
tion of patients, because half of the patients enrolled in that
study had acute DVT. Only 10% of the limbs presented
without current or previous DVT, possibly too few to
detect the thrombotic state as being predictive.
In this study, the cumulative in-stent restenosis rate
in-stent restenosis (50%) in inserted stents
estenosis 50%* (n  45) Effect† P‡ Missing values
86.3  18.9 3.78 .0002 62
0.33  0.47 1.98 .0563 167
51.4  15.5 1.23 .2182
2.51  0.94 6.78 .001 11
Fig 7. Cumulative rate of limbs with healed ulcers in patients
having stent placement alone and in those with additional proce-
dures. Limbs with ulcers that never healed were marked as un-
healed and censored at 3 months. The lower numbers represent
limbs at risk for each time interval (standard error of the mean
10%).vere
Rremained low in the long-term: 5% at 72 months. Risk
(pair
s prep
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to those for stent occlusion, but it has not been conclusively
proven that progressive in-stent restenosis results in occlu-
sion.14 Stent occlusion appears to be caused by a recurrent
thrombotic event rather than slowly evolving narrowing of
the stent. The cumulative rate of in-stent restenosis in this
study was higher in thrombotic limbs (10%) than in non-
thrombotic limbs (1%). Hartung et al33 reported a 13%
restenosis rate, but these authors appear to have included
Table V. Comparison of values before and after the proce
Chronic Venous Insufficiency Quality of Life Questionnair
Value
Leg pain (none  1, max score 5)
Work-related leg problem (not bothered  1, max score, 5)
Sleep disturbance due to leg problems (never  1, max score, 5)
Effect on social activities (none  8, max score, 40)
Effect on morale (none  9, max score, 45)
SD, Standard deviation; QOL, quality of life.
*P  .001, paired nonparametric Wilcoxon rank test.
Table VI. Hemodynamic characteristics of limbs before a
Characteristic
All limbs, n  426
AVP drop, %
VFT, s
Hand-foot pressure differential, mm Hg
Hyperemia pressure increase, mm Hg
VFI90, mL/s
VV, ml
EF, %
RVF, %
Limbs with stenting and reflux procedure, n  108
AVP drop, %
VFT, s
Hand-foot pressure differential, mm Hg
Hyperemia pressure increase, mm Hg
VFI90, mL/s
VV, mL
EF, %
RVF, %
Limbs with stenting alone, n  318
AVP drop, %
VFT, s
Hand-foot pressure differential, mm Hg
Hyperemia pressure increase, mm Hg
VFI90, mL/s
VV, mL
EF, %
RVF, %
AVP, Ambulatory venous pressure; VFT, venous filling time; VFI90, venou
fraction.
*Data are expressed as mean  SD. Only limbs with prestent and and post
†Statistical significance comparing limbs preintervention to postintervention
‡Statistical significance, comparing groups of limbs of different interventionstenosis at the lower stent-vein border area, which is notconsidered true in-stent restenosis. The mechanism of de-
velopment of in-stent restenosis is not yet known.
The present study spans a 9-year period and includes all
patients during this period of time, including the initial
“learning curve.” Increasing experience throughout the
time period has led to subsequent modification, which has
improved outcome. Stent procedures performed early in
the series sometimes needed later correction, explaining
why some of the secondary procedures were performed.
of quality of life assessment using the disease-specific
381 patients
Total score (mean  SD)
Patients with
no or little
affect on
QOL, %
Patients with
very much or
extreme affect
on QOL, %
Pre Post Pre Post Pre Post
3.5  1.1 2.6  1.2* 19% 46% 55% 26%
3.5  1.1 2.7  1.3* 18% 44% 54% 30%
3.2  1.3 2.5  1.3* 33% 57% 43% 25%
5.1  8.4 21.4  9.0* 17% 34% 25% 16%
6.0  9.8 22.1  9.7* 25% 41% 19% 12%
ter intervention*
Pre Post P
62  20 66  21† .0015
32  35 36  32† .0120
1.2  1.3 0.8  1.2† .0005
5.6  3.9 6.3  4.1 .0540
2.5  2.0 2.3  1.0† .0038
87  40 84  39† .0193
57  22 57  24 .7814
34  23 32  25 .0693
59  21 65  22† .0106
23  25 34  32† .0024
0.8  0.7 0.7  0.9 .6622
5.6  4.1 6.0  3.9 .4730
3.5  2.3 2.6  2.2† .0001
03  42 92  38† .0029
53  20 56  21 .2686
39  25 35  27 .1320
64  20‡ 68  20† .0490
34  30‡ 37  32 .1887
1.3  1.4‡ 0.8  1.2† .0003
5.7  3.8 6.4  4.1 .0670
2.2  1.8‡ 2.2  2.0 .7296
82  37‡ 81  39 .3312
58  23‡ 57  24 .7511
33  22 31  24 .2022
g index; VV, venous volume; EF, ejection fraction; RVF, residual volume
alues are included.
ed nonparametric Wilcoxon rank test).
rocedure (unpaired nonparametric Wilcoxon rank test).dure
e in
2
2nd af
1
s fillin
stent vSkipped areas between inserted stents were abandoned
paired nonparametric Wilcoxon rank test).
Statistical significant comparing limbs prestenting with poststenting (paired non
‡Statistical significance, comparing the two groups of limbs prestenting (unpaired
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patients, care was taken to avoid extension of the stent into
the IVC by placing it slightly beyond the stenosis, even
when the narrowing was at the iliocaval junction. About
40% of these stents developed proximal restenosis due to
caudad migration when a braided Wallstent was used.15
After this experience, all braided stents were inserted well
into the IVC, thus preventing caudadmigration. This is the
explanation for the secondary cephalad stent extension.
Even though the number of stents, length of stented
area, and extension of the stent underneath the inguinal
ligament into the common femoral vein are associated with
stent occlusion and development of severe in-stent resteno-
sis, the absolute numbers are low, and the stent length
should not be limited for those reasons. Stents placed in the
artery below the inguinal ligament often fracture and oc-
clude. Fractures of venous stents placed in this position
have never been reported, were not observed during this
study, and are not related to venous stent occlusion at this
site. Stent occlusions will be seen more frequently if the
venous lesions are incompletely covered.
Careful IVUS investigations have taught us that the
internal-external iliac vein confluence is stenotic in more
than half of obstructed limbs with NIVL due to compres-
sion of the external iliac vein by the internal iliac artery
diving into the pelvis.10 Secondary stenting procedures for
restenosis below the stent were due to a primarily over-
looked compression lesion at this site or a predilection of
this site for restenosis.
In the treatment of thrombotic obstruction, adequate
inflow and outflow are crucial for long-term patency. The
lower end of the stent is often placed just above the profunda-
femoral veins confluence in these limbs to ensure sufficient
thout reflux before and after stenting*
Pre Post P
1  22 63  21 .6826
6  25 27  27 .1801
.4  1.9 0.9  1.5† .0038
.8  3.9 6.8  4.4 .0581
.8  1.9 2.7  2.2 .4681
8  39 87  41 .6210
4  23 51  26 .3766
6  23 34  27 .2391
0  15‡ 75  14† .0030
7  32‡ 50  33 .6220
.4  1.5 0.8  1.1† .0157
.2  3.6 5.4  3.3 .7137
2.  0.9‡ 1.2  1.0 .9258
2  32‡ 69  33 .3666
2  23‡ 62  23 .9123
0  20 28  20 .9136
values are included (mean  SD).
parametric Wilcoxon rank test).
nonparametric Wilcoxon rank test).Table VIII. Hemodynamic characteristics of subgroups
of limbs with nonthrombotic iliac vein lesions (n  149)
and thrombotic obstruction (n  93) before and
after intervention*
Characteristic Pre Post P
AVP, drop, %
NIVL 70  18 76  12† .0006
Thrombotic 59  20‡ 60  22 .9356
VFT, s
NIVL 37  29 38  28 .3970
Thrombotic 31  30 36  35 .2067
Hand-foot pressure differential, mmHg
NIVL 1.2  1.4 0.8  1.1† .0044
Thrombotic 1.4  1.8 0.9  1.3† .0091
Hyperemia pressure increase, mmHg
NIVL 5.9  4.0 6.2  3.8 .4899
Thrombotic 5.3  3.7 6.5  4.4 .0529
VFI90, mL/s
NIVL 1.8  1.4 1.8  1.4 .6395
Thrombotic 2.7  2.0‡ 2.5  2.2 .9606
VV, ml
NIVL 88  39 81  42† .0066
Thrombotic 76  40‡ 84  38 .1710
EF, %
NIVL 56  22 61  23† .0195
Thrombotic 57  23 49  25† .0103
RVF, %
NIVL 34  22 27  21† .0063
Thrombotic 34  22 38  29 .3365
AVP, Ambulatory venous pressure; NIVL, nonthrombotic iliac vein lesion;
VFT, venous filling time; VFI90, venous filling index; VV, venous volume;
EF, ejection fraction; RVF, residual volume fraction.
*Data expressed as mean  SD. Limbs with adjunct procedures to control
superficial reflux are excluded.
†Statistical significance, comparing limbs pre-to post-intervention (paired
nonparametric Wilcoxon rank test).
‡Statistical significance, comparing groups of limbs of different etiology (un-Table VII. Hemodynamic characteristics of limbs with and wi
Characteristic
Limbs with reflux and stenting alone, n  178
AVP drop, % 6
VFT, s 2
Hand-foot pressure differential, mm Hg 1
Hyperemia pressure increase, mm Hg 5
VFI90, mL/s 2
VV, mL 8
EF, % 5
RVF, % 3
Limbs with no reflux and stenting alone, n  105
AVP drop, % 7
VFT, s 4
Hand-foot pressure differential, mm Hg 1
Hyperemia pressure increase, mm Hg 5
VFI90, mL/s 1.
VV, mL 7
EF, % 6
RVF, % 3
AVP, Ambulatory venous pressure.
*No adjunct procedures were performed. Only limbs with prestent and poststent
†inflow. IVUS imaging has been shown to be superior to
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iliofemoral occlusive lesions27,34 and should be an integral
part of the stenting technique.
Venous stenting after ultrasound-guided venous access
is performed with minimal risk.30,33,35,36 The overall rate
of thrombotic events was 4.5%, similar to 5% reported by
Hartung et al.33 Thrombosis of the stented iliac veins
occurred in 3% of all limbs and only in limbs treated for
thrombotic obstruction. Stenting of primary iliac compres-
sion lesions with the present technique had very favorable
long-term result, with no occlusions.
The extension of the stent into the IVC has raised
concerns about relative obstruction to the venous outflow
of the contralateral limb and subsequent thrombosis. The
thrombosis rate was low (1%), however, and three-fourths
of patients were stented for thrombotic obstruction. Prob-
ably because of acute onset of significant symptoms, the
patients sought immediate treatment, and the success rate
of thrombolysis or mechanical thrombectomy was high
(82%). Thus, contralateral iliac vein thrombosis related to
the IVC stent extension was generally benign and infre-
quent.
Chronic venous disease rarely threatens the survival of
the limb or the patient, so the goal is to improve symptoms
and the quality of life. The use of the VAS to measure the
amount of pain has been properly validated and is useful.28
The evaluation of swelling is semi-quantitative and less
precise. Nevertheless, mean pain score and degree of swell-
ing decreased significantly after stenting, and the propor-
tion of patients with severe pain and swelling was signifi-
cantly reduced. Complete relief of pain and swelling and
healing of an ulcer are clear end points. Cumulative free-
dom from pain was better sustained than absence of swell-
ing in the long term. The cumulative ulcer recurrence-free
rate was 58% at 5 years. Long-term cumulative relief of pain
and ulcer healing was the same in stented limbs with NIVL
and thrombotic obstruction. The long-term complete relief
of swelling was less in the NIVL limbs. The reason for this
observation is unknown.
These end points capture different expressions of the
chronic venous disease but do not provide information on the
functional impact on thepatient. For this purpose, generic and
disease-specific questionnaires have been developed to assess
the burden of disease on the individual patient as perceived by
the patient. It has previously been shown that both primary
chronic venous disease with “simple” varicose veins and dis-
ease with development of post-thrombotic stigmata signifi-
cantly reduce QOL.37-39 Specifically, previous iliofemoral
DVT may cause clinically pertinent iliac outflow obstruction
resulting in a marked compromise of QOL.7
All five problem categories of theCIVIQ formused in this
study improved significantly after stenting of both NIVL and
thrombotic outflow obstructions. Chronic venous disease,
regardless of etiology, affects QOL adversely, and stenting in
patients with chronic venous outflow obstruction frequently
markedly improved QOL. Significant improvement of Ve-
nous Clinical Severity and Venous Disability Scores has previ-
ously been reported by Hartung et al.33The hemodynamic changes using conventional meth-
ods were relatively minor compared with the clinical im-
provement. A few observations are noteworthy. Better
results for reflux-related variables (VFT, VFI90, and VV)
after treatment were observed only when adjunct saphe-
nous procedures were combined with the stenting. In no
subset of patients was a deterioration of venous reflux
observed. An increase of reflux in a small group of post-
thrombotic limbs after stenting has been reported.40 Axial
deep reflux present before stenting did not, however,
worsen the global reflux measurably after stenting in this
study. The contention that the stenting of the proximal
venous outflow obstruction would result in the loss of
protection or buffering of retrograde reflux was not sup-
ported by these observations.
Significant decrease of the mean hand-foot pressure
differential in stented limbs occurred with and without
remaining reflux and no adjunct procedures, and ambula-
tory venous pressure improved in most subsets of limbs.
Although numerically small, these changes were statistically
significant and indicated that the outflow obstruction was
alleviated and the global hemodynamics improved after
stenting.16 Before stenting, limbs with thrombotic ob-
struction clearly had more extensive venous disease with
more severe obstruction and reflux more frequently involv-
ing multiple systems and levels than limbs with NIVL.
Despite this observation, stenting improved clinical symp-
toms andQOL substantially and similarly in both groups of
patients. The positive clinical outcome was achieved with
an improvement of the calf muscle pump function in the
NIVL limbs, whereas the thrombotic limbs had no measur-
able hemodynamic improvement in these indicators. The
hemodynamic response in patients who became completely
free of pain and swelling or whose ulcers healed was no
different than in those with residual pain or swelling or
nonhealing ulcers. The lack of improvement of conven-
tional hemodynamic test results underscores the poor un-
derstanding of the pathophysiology and the inability to
accurately test hemodynamically significant venous ob-
struction.
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Appendix Table EII (online only). Type of adjunct
procedures to venous stenting performed to control
superficial venous reflux
Type of procedure No.
GSV laser ablation* 52
GSV stripping* 68
GSV radiofrequency closure* 55
SSV stripping 7
Stab avulsions 15
Total number of interventions 197
GSV, great saphenous vein; SSV, small saphenous vein.
*GSV procedures combined with SSV stripping in 7 limbs, stab avulsion in
75 limbs.f hemodynamic and lymphatic studies
Description
trast medium into the common femoral or femoral vein was made to
distribution and nature of femoroiliocaval morphologic changes,
lusion, stenosis, and presence of collateral circulation, as well as to
of inserted iliofemoral stents. Ascending venogram with injection of
um into a dorsal foot vein was occasionally used to evaluate stent
ot the degree of in-stent restenosis.
ux 0.5 seconds was considered significant. The pattern of reflux was
o ways:
l fashion, mimicking Kistner’s classification, giving 1 to 4 points as
lved in the common femoral, femoral, popliteal, and distal posterior
nsecutively; and
ment score, with 1 point each awarded to the femoral, profunda,
terior tibial, above and below knee great saphenous, and small
ns (maximum score  7), whether or not axial reflux was present.21-23
hing below the popliteal vein (ie, Kistner classes 3 and 4) was
ial.
s recorded in the dorsal vein with the patient standing erect and
d holding onto a frame, during 10 toe-stands, and throughout the
sure recovery to baseline level. The ambulatory venous
) was measured as the percentage drop of baseline pressure at rest to
e end of the exercise and reflects global venous hemodynamics. The
for the pressure to return to base level was the venous filling
seconds), reflecting mainly venous reflux.
ferential between a needle placed in the dorsal foot vein and a hand
levels with the right atrium of the heart, was measured (normal, 4
r reactive hyperemia induced by ischemia using a cuff, the rise of the
essure was measured (normal, 8 mm Hg). An individual or
ormal test defines grade 2 to 4 of outflow obstruction.
thysmography using APG-1000 (ACI Medical Inc., Sun Valley, Calif)
cribed by Christopolous et al.26 Venous filling index (VFI90, mL/s),
0% of total increase of calf volume when shifting from the supine to
tion, has been shown to be a useful parameter to reflect global venous
dition, venous volume (VV, mL), ejection fraction, and residual
n of the calf were measured. The ejection fraction and residualAppendix Fig (online only). Cumulative primary, assisted-primary,
and secondary patency rates in a subset of limbs stented after
recanalization of post-thrombotic occlusion. The lower numbers
represent total limbs at risk for each time interval (all standard error
of the mean 10%).
